News
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses…
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the…
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research 2021 Annual Meeting
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021…
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO…
Published Research in Nature Communications: PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity
Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional…
Partner News: UConn Health Opens New Cancer Trial with PVSRIPO
From the office of UConn Health: High-Profile Brain Tumor Trial Chooses UConn Health An immunotherapy…
Press Release: FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced…
Press Release: Istari Announces 1st Patient in LUMINOS-101 Trial of PVSRIPO with Pembrolizumab for rGBM
Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO…
Partner News: UH Seidman Cancer Center Opens New Trial with PVSRIPO
From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New…
Press Release: Istari to Open LUMINOS-102 Trial in Treatment-Refractory Melanoma
Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without…